And the winner is TAKEDA ! (they've finished their "look @ the books" evaluation, which I'm sure they paid AMLN 1/4 $M to do so )
Their offer will be $37ish - it will be rejected & countered for a final price of $42.
There you go - remember who told you first. And the deal is annouced soon & closed by yr end.
Takeda California is Takeda's Center of Excellence and Innovation for Structure-Based Drug Discovery and Protein Therapeutics. The company combines cutting-edge protein x-ray crystallography, small molecule, antibody, and antibody drug-conjugate capabilities to efficiently generate potential new medicines for treating cancer, inflammatory diseases and metabolic diseases. Multiple potential new drugs invented at Takeda California are in clinical trials evaluation including NESINA® (generic name Alogliptin) which was approved for treating patients with type II diabetes in Japan in 2010.
Takeda California is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Japan's largest pharmaceutical company and one with a 230-year heritage. Together with its worldwide partners in science, Takeda California is committed to strive toward better health for patients through leading innovation in medicine.